Clinical Trials | March 09, 2026
DiaMedica bags Health Canada nod for Phase 2 preeclampsia trial
DiaMedica said it plans to launch the trial later in 2026
DiaMedica said it plans to launch the trial later in 2026
This study evaluated a difficult-to-treat Crohn's disease patient population
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
Duvakitug was well tolerated and safety was consistent with the induction study
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
Improvements were also seen in complete response rates, duration of response, and time to next treatment
Subscribe To Our Newsletter & Stay Updated
